LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Suletud

Sektor Tervishoid

16.09 -0.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

15.97

Max

16.09

Põhinäitajad
By Trading Economics
Sissetulek	17M 33M
Müük	36M 242M
Aktsiakasum	0.2
Kasumimarginaal	13.797
Töötajad	597
EBITDA	12M 33M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+67.58 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	119M 2.7B
Eelmine avamishind	16.71
Eelmine sulgemishind	16.09

Uudiste sentiment

By Acuity

100%

340 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

15.69 / 16.33 Toetus ja vastupanu

ACADIA Pharmaceuticals Inc Graafik

Seotud uudised

6. sept 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6. sept 2024, 21:18 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6. sept 2024, 21:05 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6. sept 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. sept 2024, 20:39 UTC

Tulu

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6. sept 2024, 20:35 UTC

Peamised uudised

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6. sept 2024, 20:34 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6. sept 2024, 20:11 UTC

Peamised uudised

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6. sept 2024, 19:51 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6. sept 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6. sept 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6. sept 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6. sept 2024, 18:27 UTC

Peamised uudised

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6. sept 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6. sept 2024, 18:15 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6. sept 2024, 18:12 UTC

Peamised uudised

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6. sept 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6. sept 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6. sept 2024, 17:30 UTC

Peamised uudised

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6. sept 2024, 17:27 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6. sept 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. sept 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6. sept 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6. sept 2024, 16:35 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6. sept 2024, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6. sept 2024, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

6. sept 2024, 16:20 UTC

Tulu

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6. sept 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. sept 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. sept 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

ACADIA Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

67.58% tõus

12 kuu keskmine prognoos

Keskmine 26.93 USD 67.58%

Kõrge 39 USD

Madal 17 USD

Põhineb 18 Wall Streeti analüütiku instrumendi ACADIA Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi ACADIA Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

15.69 / 16.33Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

340 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).